-Nicholas C P Cross Researcher Activity Profile

Research Author Detailed Information 

Nicholas C P Cross Publication Rate By Year

Nicholas C P Cross has published 2 paper(s) in 2006, 15 paper(s) in 2007, 2 paper(s) in 2008, for a total of 19 research publications in total.

Nicholas C P Nc Cross Author Information

LAST NAME: cross

FIRST NAME: Nicholas C P

INITIALS: nc

AFFILIATION:

Papers

Nicholas C P Cross's Publication Record

1. Simultaneous MLPA-based multiplex point mutation and deletion analysis of the dystrophin gene. Year Published: 2007
National Genetics Reference Laboratory (Wessex), Salisbury Hospital NHS Trust, Salisbury, Wiltshire, SP2 8BJ. Dave.Bunyan@salisbury.nhs.uk
2. [Application of denaturing high performance liquid chromatography to mutation detection of the c-kit gene in mastocytosis] Year Published: 2006
Department of Hematology, Shandong Provincial Hospital, Jinan 250021 China. zlyzly2002@hotmail.com
3. Diagnostic and therapeutic management of eosinophilia-associated chronic myeloproliferative disorders. Year Published: 2007
4. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Year Published: 2007
Section of Haemato-Oncology, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, UK.
5. Methylation-sensitive high-resolution melting-curve analysis of the SNRPN gene as a diagnostic screen for Prader-Willi and Angelman syndromes. Year Published: 2007
National Genetics Reference Laboratory (Wessex), Salisbury District Hospital, Odstock, Salisbury, Wiltshire, United Kingdom. H.E.White@soton.ac.uk
6. A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy. Year Published: 2007
Wessex Regional Genetics Laboratory, University of Southampton, Salisbury, UK. F.H.Grand@soton.ac.uk
7. Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. Year Published: 2007
Wessex Regional Genetics Laboratory, Salisbury and Human Genetics Division, University of Southampton, Southampton, United Kingdom.
8. No evidence for amplification of V617F JAK2 in myeloproliferative disorders. Year Published: 2007
9. The severity of FIP1L1-PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus. Year Published: 2007
Wessex Regional Genetics Laboratory, University of Southampton, Salisbury, UK.
10. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Year Published: 2007
Section of Haemato-Oncology, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, UK.
11. Methylation-sensitive high-resolution melting-curve analysis of the SNRPN gene as a diagnostic screen for Prader-Willi and Angelman syndromes. Year Published: 2007
National Genetics Reference Laboratory (Wessex), Salisbury District Hospital, Odstock, Salisbury, Wiltshire, United Kingdom. H.E.White@soton.ac.uk
12. [Application of denaturing high performance liquid chromatography to mutation detection of the c-kit gene in mastocytosis] Year Published: 2006
Department of Hematology, Shandong Provincial Hospital, Jinan 250021 China. zlyzly2002@hotmail.com
13. No evidence for amplification of V617F JAK2 in myeloproliferative disorders. Year Published: 2007
14. The severity of FIP1L1-PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus. Year Published: 2007
Wessex Regional Genetics Laboratory, University of Southampton, Salisbury, UK.
15. A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy. Year Published: 2007
Wessex Regional Genetics Laboratory, University of Southampton, Salisbury, UK. F.H.Grand@soton.ac.uk
16. Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. Year Published: 2007
Wessex Regional Genetics Laboratory, Salisbury and Human Genetics Division, University of Southampton, Southampton, United Kingdom.
17. Evaluation of JAK2 in B and T cell neoplasms: identification of JAK2(V617F) mutation of undetermined significance (JMUS) in the bone marrow of three individuals. Year Published: 2008
Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA. lyw2001@med.cornell.edu
18. Diagnostic and therapeutic management of eosinophilia-associated chronic myeloproliferative disorders. Year Published: 2007
19. Evaluation of JAK2 in B and T cell neoplasms: identification of JAK2(V617F) mutation of undetermined significance (JMUS) in the bone marrow of three individuals. Year Published: 2008
Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA. lyw2001@med.cornell.edu